Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project.
暂无分享,去创建一个
R. Krauss | W. Haskell | E. Alderman | J. Fair | B. Miller | Bonnie Miller
[1] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[2] P. Tijssen,et al. Practice and theory of enzyme immunoassays , 1985 .
[3] C. Packard,et al. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[4] R. Krauss,et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.
[5] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[6] W C Willett,et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.
[7] R. Krauss,et al. Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. , 1992, Journal of lipid research.
[8] P. Wilson,et al. Effect of Gender, Age, and Lipid Status on Low Density Lipoprotein Su bf raction Distribution: Results from the Framingham Offspring Study , 1987, Arteriosclerosis.
[9] C. Packard,et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. , 1994, Atherosclerosis.
[10] G. Watts,et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.
[11] V. Schumaker,et al. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. , 1994, Advances in protein chemistry.
[12] A. Slyper,et al. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. , 1994, JAMA.
[13] R. Krauss. Heterogeneity of plasma low‐density lipoproteins and atherosclerosis risk , 1994, Current opinion in lipidology.
[14] D H Blankenhorn,et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. , 1990, Circulation.
[15] V. Fuster,et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. , 1988, Journal of the American College of Cardiology.
[16] W. Santamore,et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.
[17] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[18] K. Gould,et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.
[19] S. Azen,et al. Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.
[20] R. Krauss,et al. Detection and quantitation of LDL subfractions , 1992 .
[21] E L Bolson,et al. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. , 1986, Circulation.
[22] Effects of the lipid intervention in the Stanford Coronary Risk Intervention Project , 1996 .
[23] D. Waters,et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.
[24] B. G. Brown,et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. , 1994, Journal of the American College of Cardiology.
[25] Stanley Azen,et al. Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.
[26] M J Malloy,et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.
[27] G. Nelson. Blood Constituents. (Book Reviews: Blood Lipids and Lipoproteins. Quantitation, Composition, and Metabolism) , 1972 .